The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation (NBDF) for a ...

Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...

After UCB’s Bimzelx scored five approvals just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...

Over the last year, Viatris has been busy working to resolve FDA concerns at a critical drug manufacturing plant in India ...

The committee’s reputation has taken a nosedive, however, following HHS Secretary Robert F. Kennedy Jr.’s decision to purge ...

The nod allows Hernexeos (zongertinib) to be used as an initial treatment option for NSCLC with HER2-activating mutations in ...

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities.  | In a Worker Adjustment and Retraining Notification Act alert filed this ...

Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...